相关实验视频

Updated: May 15, 2025

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

An Efficient and Simple Method to Establish NK and T Cell Lines from Patients with Chronic Active Epstein-Barr Virus Infection

Published on: March 30, 2018

桑古纳林抑制EBV阳性扩散大B细胞淋巴瘤的细胞生长

Suli Lu¹, Dae-Jung Yang²

¹Department of Medicine, Hunan Polytechnic of Environment and Biology, Hengyang, Hunan 421005, China.

Archivum immunologiae et therapiae experimentalis

|April 8, 2025

概括

桑瓜林 (SAG) 通过诱导细胞循环停止和亡来抑制爱斯坦-巴尔病毒阳性扩散性大B细胞淋巴瘤 (DLBCL) 的生长. 这种化合物向Wnt/β-catenin通路,为DLBCL提供潜在的治疗策略.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
药理学药理学是指药理学的学科.

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 是一种侵略性的非霍奇金淋巴瘤.
爱斯坦-巴尔病毒 (EBV) 阳性是DLBCL病例的一个子集的特征.
针对特定的分子通路对于开发新型DLBCL疗法至关重要.

研究的目的:

为了研究血红素 (SAG) 对EBV阳性DLBCL细胞系的抗癌作用.
阐明SAG作用的潜在分子机制.
探索SAG作为DLBCL的潜在治疗剂.

主要方法:

使用了EBV阳性DLBCL细胞系 (FARAGE,GM12878S).使用了EBV阳性DLBCL细胞系 (FARAGE,GM12878S).
使用细胞计数工具-8和氧氨测试评估细胞增殖.
通过流细胞计和免疫阻塞分析了细胞循环停止和细胞亡.
研究了分子机制,包括Wnt/β-catenin通路,使用免疫阻塞.

主要成果:

这种SAG显著抑制了EBV阳性DLBCL细胞的增殖.
治疗SAG导致细胞循环停止,并在这些细胞中诱导了细胞亡.
机械上,SAG被发现可以抑制Wnt/β-catenin信号通路.

结论:

桑古纳林在体外对EBV阳性DLBCL细胞表现出强烈的抗增殖和促的作用.
在抑制DLBCL进展方面,Wnt/β-catenin通路是SAG的一个关键目标.
萨格证明了作为EBV阳性DLBCL的治疗候选者的潜力.

关键词:

细胞灭亡 (apoptosis) 是一种死亡的过程.细胞循环的细胞周期有EBV阳性的DLBCLL.一个血的血.在Wnt/β-catenin中使用.

更多相关视频

A Simple Red Blood Cell Lysis Method for the Establishment of B Lymphoblastoid Cell Lines

A Simple Red Blood Cell Lysis Method for the Establishment of B Lymphoblastoid Cell Lines

Published on: January 14, 2017

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Isolation and Quantification of Epstein-Barr Virus from the P3HR1 Cell Line

Published on: September 28, 2022

相关概念视频

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...